The pharmacokinetic and pharmacodynamic effects of SL65.1498,a GABA-A 2,3 selective agonist,in comparison with lorazepam in healthy volunteers

Abstract

Benzodiazepines are effective short-term treatments for anxiety disorders, but their use is limited by undesirable side effects related to Central Nervous System impairment and tolerance development. SL65.1498 is a new compound that acts in vitro as a full agonist at the γ-aminobutyric acid_A 2 and 3 receptor and as a partial agonist at the 1 and 5 receptor subtypes. It is thought that the compound could be anxiolytic by its activation at the alpha2 and alpha3 receptor subtypes, without causing unfavourable side effects, which are believed to be mediated by the alpha1 and alpha5 subtypes. This study was a double-blind, five-way cross-over study to investigate the effects of three doses of SL65.1498 in comparison with placebo and lorazepam 2 mg in healthy volunteers. The objective was to select a dose level (expected to be therapeutically active), free of any significant deleterious effect. Psychomotor and cognitive effects were measured using a validated battery of measurements, including eye movements, body sway, memory tests, reaction-time assessments, and visual analogue scales. The highest dose of SL65.1498 showed slight effects on saccadic peak velocity and smooth pursuit performance, although to a much lesser extent than lorazepam. In contrast to lorazepam, none of the SL65.1498 doses affected body sway, visual analogue scale alertness, attention, or memory tests. This study showed that the three doses of SL65.1498 were well tolerated and induced no impairments on memory, sedation, psychomotor, and cognitive functions.

Keywords

benzodiazepines body sway memory saccadic eye movements sedation selective partial GABA agonist SL65.1498

Get full access to this article

View all access options for this article.

References

Aldenkamp A Vermeulen J Alpherts WCJ Overweg J van Parijs JAP Verhoeff NPLG (1992) Validity of computerized testing: patient dysfunction and complaints versus measured changes. In: WE Dodson M Kinsbourne (eds), Assessment of Cognitive Function, New York: Demos, pp. 51-68.

Alpherts WCJ (1987) Computers as a technique for neurphysiological assessment in epilepsy. In: AP Aldenkamp WCJ Alpherts H Meinardi G Stores (eds), Education and Epilepsy. Lisse/Berwyn: Swets & Zeitlinger, pp. 101-109.

Baloh RW Sills AW Kumley WE Honrubia V (1975) Quantitative measurement of saccade amplitude, duration, and velocity. Neurology 25: 1065-1070.

Bittencourt PR Wade P Smith AT Richens A (1981) The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration. Br J Clin Pharmacol 12: 523-533.

Blin O Jacquet A Callamand S Jouve E Habib M Gayraud D (1999) Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers. Br J Clin Pharmacol 48: 510-512.

Bond A Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.

Cohen AF Hamilton MJ Peck AW (1987) The effects of acrivastine (BW825C), diphenhydramine and terfenadine in combination with alcohol on human CNS performance. Eur J Clin Pharmacol 32: 279-288.

de Haas SL de Visser SJ van der Post JP de Smet M Schoemaker RC Rijnbeek B (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA 2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 21: 374-383.

de Haas SL de Visser SJ van der Post JP Schoemaker RC van Dyck K Murphy MG Gerven, JMAv (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 22: 24-32.

10.

de Visser SJ van der Post JP de Waal PP Cornet F Cohen AF van Gerven JM (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55: 39-50.

11.

Glue P White E Wilson S Ball DM Nutt DJ (1991) Pharmacology of saccadic eye movements in man. 2. Effects of the alpha 2-adrenoceptor ligands idazoxan and clonidine. Psychopharmacology (Berl) 105: 368-373.

12.

Green JF McElholm A King DJ (1996) A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology (Berl) 128: 67-73.

13.

Greenblatt DJ (1981) Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 6: 89-105.

14.

Griebel G Perrault G Simiand J Cohen C Granger P Decobert M (2001) SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther 298: 753-768.

15.

Griebel G Perrault G Simiand J Cohen C Granger P Depoortere H (2003) SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev 9: 3-20.

16.

Izaute M Bacon E (2005) Specific effects of an amnesic drug: effect of lorazepam on study time allocation and on judgment of learning. Neuropsychopharmacology 30: 196-204.

17.

Licata SC Platt DM Cook JM Sarma PV Griebel G Rowlett JK (2005) Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]. J Pharmacol Exp Ther 313: 1118-1125.

18.

Low K Crestani F Keist R Benke D Brunig I Benson JA (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290: 131-134.

19.

Micallef J Soubrouillard C Guet F Le Guern ME Alquier C Bruguerolle B (2001) A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundam Clin Pharmacol 15: 209-216.

20.

Nelson RE Dickson AL Banos JH (2000) An automated administration of Corsi's Block-tapping Test. Percept Mot Skills 91: 578-580.

21.

Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.

22.

Rubinsztein JS Rogers RD Riedel WJ Mehta MA Robbins TW Sahakian BJ (2001) Acute dietary tryptophan depletion impairs maintenance of affective set and delayed visual recognition in healthy volunteers. Psychopharmacology (Berl) 154: 319-326.

23.

Rudolph U Crestani F Mohler H (2001) GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22: 188-194.

24.

Schmitt JA Jorissen BL Sobczak S van Boxtel MP Hogervorst E Deutz NE (2000) Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol 14: 21-29.

25.

Sieghart W (1995) Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 47: 181-234.

26.

van Steveninck AL Cohen AF Ward T (1989) A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements. Br J Clin Pharmacol 27: 712P-713P.

27.

van Steveninck AL Gieschke R Schoemaker RC Roncari G Tuk B Pieters MS (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 41: 565-573.

28.

van Steveninck AL Schoemaker HC Pieters MS Kroon R Breimer DD Cohen AF (1991) A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 50: 172-180.

29.

van Steveninck AL van Berckel BN Schoemaker RC Breimer DD van Gerven JM Cohen AF (1999) The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol 13: 10-17.

30.

van Steveninck AL Verver S Schoemaker HC Pieters MS Kroon R Breimer DD (1992) Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther 52: 402-408.

31.

Wright BM (1971) A simple mechanical ataxia-meter. J Physiol 218: 27P-28P.